Clinical Significance of Anti-HEV IgA in Diagnosis of Acute Genotype 4 Hepatitis E Virus Infection Negative for Anti-HEV IgM

Zhang, Shujun; Tian, Di; Zhang, Zhengang; Xiong, Junhui; Yuan, Quan; Ge, Shengxiang; Zhang, Jun; Xia, Ningshao

doi:10.1007/s10620-008-0657-4

Cited by 37 publications

(29 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Marked variability in the sensitivity and specificity of HEV assays complicates the interpretation and comparison of serologic studies (193)(194)(195)(196)(197)(198)(199), and this fact should be borne in mind when considering the serologic data presented in this section and elsewhere. Studies with early anti-HEV IgM and IgG commercial assays often failed to detect seropositive individuals, undercounting the seroprevalence (200).…”

Section: Scope and Duration Of Protective Immunity To Hev Following Imentioning

confidence: 99%

“…Case reports and clinical studies from Europe have also raised suspicions about serologic cross-reactivity in the presence of other viral infections, such as Epstein-Barr virus (EBV) or cytomegalovirus (CMV) (201,202). Several recent serologic assays and other diagnostic methods have been found to have improved performance in a wide range of settings (194,198,(203)(204)(205)(206)(207).…”

Section: Scope and Duration Of Protective Immunity To Hev Following Imentioning

confidence: 99%

See 1 more Smart Citation

Host Immune Status and Response to Hepatitis E Virus Infection

2014

View full text Add to dashboard Cite

SUMMARY Hepatitis E virus (HEV), identified over 30 years ago, remains a serious threat to life, health, and productivity in developing countries where access to clean water is limited. Recognition that HEV also circulates as a zoonotic and food-borne pathogen in developed countries is more recent. Even without treatment, most cases of HEV-related acute viral hepatitis (with or without jaundice) resolve within 1 to 2 months. However, HEV sometimes leads to acute liver failure, chronic infection, or extrahepatic symptoms. The mechanisms of pathogenesis appear to be substantially immune mediated. This review covers the epidemiology of HEV infection worldwide, the humoral and cellular immune responses to HEV, and the persistence and protection of antibodies produced in response to both natural infection and vaccines. We focus on the contributions of altered immune states (associated with pregnancy, human immunodeficiency virus [HIV], and immunosuppressive agents used in cancer and transplant medicine) to the elevated risks of chronic infection (in immunosuppressed/immunocompromised patients) and acute liver failure and mortality (among pregnant women). We conclude by discussing outstanding questions about the immune response to HEV and interactions with hormones and comorbid conditions. These questions take on heightened importance now that a vaccine is available.

show abstract

Section: Scope and Duration Of Protective Immunity To Hev Following Imentioning

confidence: 99%

Section: Scope and Duration Of Protective Immunity To Hev Following Imentioning

confidence: 99%

Host Immune Status and Response to Hepatitis E Virus Infection

2014

View full text Add to dashboard Cite

show abstract

“…Currently, a rapid immunochromatographic test is available to detect IgM antibodies in acute hepatitis E that works on the basis of reverse-flow technology and yields results in a matter of 2–3 min [63]. Anti-HEV IgA antibody detection could be used as a supplementary means to prove the acute disease if an anti-HEV IgM antibody test fails to do so [64]. It has not been determined whether anti-HEV IgA plays a major role in the detection of HEV nosocomial outbreaks or not.…”

Section: Diagnosis Of Hev Infection In Hd Patients and Renal Allografmentioning

confidence: 99%

Hepatitis E Virus Infection: A General Review with a Focus on Hemodialysis and Kidney Transplant Patients

Hosseini-Moghaddam¹,

Abbaszadeh²,

Alavian³

et al. 2010

Am J Nephrol

View full text Add to dashboard Cite

Background: Hepatitis E virus (HEV) infection is a self-limited viral disease that causes acute hepatitis epidemics in developing countries. The common route of transmission for HEV is supposedly fecal-oral. Serological evidence may be unexpectedly found in hemodialysis (HD) patients and kidney transplant recipients. Although the route of HEV transmission is not usually determined in HD subjects, this virus seems to be transmitted either directly through HD or nosocomially. In this study, we gathered the published information on HEV infection in HD patients and kidney transplant recipients. Methods: For this review, we collected the relevant articles by searching through Medline and Google Scholar from January 1980 up to September 2009. Results: Some variables including older age, low education, living in rural versus urban areas and the duration of HD seem to be risk factors for HEV infection in HD patients. Compared with non-HD subjects, HEV infection may be specifically associated with poor outcome in HD patients. Specific considerations seem to be required to prevent transmission of HEV to HD patients. Conclusion: More extensive investigations are required to determine the disease burden of HEV infection in HD subjects in countries which experience outbreaks of HEV infection.

show abstract

“…Previous studies have reported that the detection of anti-HEV IgA is a convenient complementary marker for the diagnosis of HEV infection [88,89,90], especially regarding the enhanced specificity of a combination of both anti-HEV IgM and IgA immunoglobulins. Like IgM, IgA anti-HEV antibodies appear during acute hepatitis E. However, Herremans and coworkers [90] reported infections with HEV genotype 3 without an increase of IgA antibodies.…”

Section: Laboratory Diagnosismentioning

confidence: 99%

Autochthonous Hepatitis E Virus Infections: A New Transfusion-Associated Risk?

Dreier

Juhl²

2013

Transfus Med Hemother

View full text Add to dashboard Cite

Hepatitis E virus (HEV) has been recognized since 2004 as a transfusion-transmissible infectious agent, and recent epidemiological data suggest that it may pose a safety threat to the blood supply. It has recently become obvious that hepatitis E is endemic in industrialized countries, and that more infections are autochthonous than travel-associated. Epidemiological and phylogenetic analysis suggests that HEV infection has to be considered as a zoonosis and that viral transmission from animals (pigs, wild animals) occurs through food or direct contact. The seroprevalence and incidence of HEV in the general population and blood donors in European countries indicate an underestimated risk for transfusion transmissions. Recently reported cases of transfusion transmission of HEV infection, and detection of viremic, asymptomatic blood donors in nucleic acid amplification technique screening programs give an indication of the importance of this virus. Diagnostic assays for detection of anti-HEV antibodies, HEV antigens and RNA are discussed. Recent studies support the idea that active immunization can prevent hepatitis E, highlighting the need for vaccination programs. Here we review current knowledge of HEV and its epidemiology, blood transmission and prevention of this disease with emphasis on blood supply.

show abstract

Clinical Significance of Anti-HEV IgA in Diagnosis of Acute Genotype 4 Hepatitis E Virus Infection Negative for Anti-HEV IgM

Cited by 37 publications

References 28 publications

Host Immune Status and Response to Hepatitis E Virus Infection

Host Immune Status and Response to Hepatitis E Virus Infection

Hepatitis E Virus Infection: A General Review with a Focus on Hemodialysis and Kidney Transplant Patients

Autochthonous Hepatitis E Virus Infections: A New Transfusion-Associated Risk?

Contact Info

Product

Resources

About